Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
11
12
2018
revised:
28
01
2019
accepted:
21
03
2019
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
24
5
2019
Statut:
ppublish
Résumé
The Memorial Sloan Kettering Cancer Center (MSK) colon cancer recurrence nomogram is a risk calculator that provides patients and clinicians with individualized prediction of recurrence following curative resection of colon cancer. Although validated on multiple separate cohorts, the nomogram requires periodic updating as patient care changes over time. The aim of this study was to evaluate the nomogram's accuracy in a contemporary cohort and modify the tool to reflect improvements in outcome related to advances in colon cancer therapy. A contemporary patient cohort was compiled, including consecutive colon cancer patients undergoing curative resection for stage I-III colon adenocarcinoma at MSK from 2007 to 2014. The nomogram's predictive accuracy was assessed by concordance index and calibration plots of predicted vs actual freedom from recurrence at 5 years after surgery. Data from a total of 999 eligible patients with complete records were used for validation. Median follow-up among survivors was 37 months. The concordance index was 0.756 (95% confidence interval = 0.707 to 0.805), indicating continued discriminating power, but the calibration plot revealed that the nomogram overestimated recurrence risk. Recalibration of the nomogram by estimating a new baseline freedom-from-recurrence function restored the nomogram's accuracy. The updated nomogram retains the original nomogram's variables but includes a lower baseline estimation of recurrence risk, reflecting improvements in outcomes for all stages of colon cancer, likely resulting from advances in imaging and integration of multiple treatment modalities.
Sections du résumé
BACKGROUND
BACKGROUND
The Memorial Sloan Kettering Cancer Center (MSK) colon cancer recurrence nomogram is a risk calculator that provides patients and clinicians with individualized prediction of recurrence following curative resection of colon cancer. Although validated on multiple separate cohorts, the nomogram requires periodic updating as patient care changes over time. The aim of this study was to evaluate the nomogram's accuracy in a contemporary cohort and modify the tool to reflect improvements in outcome related to advances in colon cancer therapy.
METHODS
METHODS
A contemporary patient cohort was compiled, including consecutive colon cancer patients undergoing curative resection for stage I-III colon adenocarcinoma at MSK from 2007 to 2014. The nomogram's predictive accuracy was assessed by concordance index and calibration plots of predicted vs actual freedom from recurrence at 5 years after surgery.
RESULTS
RESULTS
Data from a total of 999 eligible patients with complete records were used for validation. Median follow-up among survivors was 37 months. The concordance index was 0.756 (95% confidence interval = 0.707 to 0.805), indicating continued discriminating power, but the calibration plot revealed that the nomogram overestimated recurrence risk. Recalibration of the nomogram by estimating a new baseline freedom-from-recurrence function restored the nomogram's accuracy.
CONCLUSION
CONCLUSIONS
The updated nomogram retains the original nomogram's variables but includes a lower baseline estimation of recurrence risk, reflecting improvements in outcomes for all stages of colon cancer, likely resulting from advances in imaging and integration of multiple treatment modalities.
Identifiants
pubmed: 31119207
doi: 10.1093/jncics/pkz015
pii: pkz015
pmc: PMC6512350
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkz015Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Arch Pathol Lab Med. 2000 Jul;124(7):979-94
pubmed: 10888773
Stat Med. 2000 Dec 30;19(24):3401-15
pubmed: 11122504
Radiology. 2001 Jan;218(1):55-60
pubmed: 11152779
Rofo. 2002 Apr;174(4):452-8
pubmed: 11960408
J Clin Oncol. 2004 May 15;22(10):1797-806
pubmed: 15067028
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5
pubmed: 15467030
AJR Am J Roentgenol. 2005 Jul;185(1):239-46
pubmed: 15972430
Eur Radiol. 2006 Jun;16(6):1337-45
pubmed: 16453115
Lancet. 2007 Dec 15;370(9604):2020-9
pubmed: 18083404
J Clin Oncol. 2008 Jan 20;26(3):380-5
pubmed: 18202413
AJR Am J Roentgenol. 1991 Oct;157(4):731-9
pubmed: 1892027
Colorectal Dis. 2009 May;11(4):354-64; discussion 364-5
pubmed: 19016817
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
J Clin Oncol. 2009 Dec 20;27(36):6166-71
pubmed: 19901106
Radiology. 2010 Dec;257(3):674-84
pubmed: 20829538
Clin Colorectal Cancer. 2012 Jun;11(2):138-42
pubmed: 22018885
J Clin Oncol. 2011 Dec 20;29(36):4796-802
pubmed: 22084366
J Clin Oncol. 2012 May 20;30(15):1763-9
pubmed: 22473170
Lancet. 1986 Jun 28;1(8496):1479-82
pubmed: 2425199
Eur J Surg Oncol. 2014 May;40(5):545-550
pubmed: 24491289
Ann Surg. 2015 Apr;261(4):708-15
pubmed: 25072438
J Natl Cancer Inst. 2014 Oct 29;106(12):null
pubmed: 25359867
Lancet Oncol. 2015 Feb;16(2):161-8
pubmed: 25555421
Ann Surg Oncol. 2015 Nov;22(12):3881-7
pubmed: 25963477
CA Cancer J Clin. 2016 Sep;66(5):370-4
pubmed: 26784705
Int J Surg. 2016 Mar;27:58-65
pubmed: 26796369
Br J Surg. 2016 Aug;103(9):1220-9
pubmed: 27222317
J Surg Oncol. 2017 Dec;116(8):969-982
pubmed: 28767139
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Radiology. 1996 Aug;200(2):443-51
pubmed: 8685340
AJR Am J Roentgenol. 1998 May;170(5):1341-7
pubmed: 9574613